Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

13.0K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
13.0K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

667
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
667
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

694
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
694
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

4.4K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
4.4K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

724
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
724

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental design in formulation optimization of vitamin K<sub>1</sub> oxide-loaded nanoliposomes for skin delivery.

International journal of pharmaceutics·2020
Same author

Mesoporous silica nanoparticles for enhanced lidocaine skin delivery.

International journal of pharmaceutics·2018
Same author

Nanodiamond applications in skin preparations.

Drug discovery today·2018
Same author

RNA Loading on Nano-Structured Hyperbranched β-Cyclodextrin.

Avicenna journal of medical biotechnology·2018
Same author

Fullerene nanoparticle in dermatological and cosmetic applications.

Nanomedicine : nanotechnology, biology, and medicine·2016
Same author

New Generation of Fluconazole: A Review on Existing Researches and Technologies.

Current drug delivery·2016

Related Experiment Video

Updated: Apr 15, 2026

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide
08:01

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide

Published on: June 28, 2019

8.0K

Arsenic trioxide binding to serum proteins.

Sara Shooshtary1, Sima Behtash1, Shohreh Nafisi2

  • 1Department of Chemistry, IAU, Central Tehran Branch (IAUCTB), Tehran, Iran.

Journal of Photochemistry and Photobiology. B, Biology
|April 13, 2015
PubMed
Summary

Arsenic trioxide (ATO), an anticancer drug, binds effectively to human and bovine serum albumin. These proteins show potential as carriers for delivering ATO, despite some structural changes upon binding.

Keywords:
Arsenic trioxideBovine serum albuminFT-IRHuman serum albuminUV–Vis spectroscopy

More Related Videos

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
09:23

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

10.4K
TD-DFT Guided Advanced E-Eye Sensing Technique for On-site Quantification of Fe, Cr, F, and As in the Environmental, Biological, and Food Samples
09:51

TD-DFT Guided Advanced E-Eye Sensing Technique for On-site Quantification of Fe, Cr, F, and As in the Environmental, Biological, and Food Samples

Published on: September 19, 2025

608

Related Experiment Videos

Last Updated: Apr 15, 2026

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide
08:01

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide

Published on: June 28, 2019

8.0K
Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
09:23

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

10.4K
TD-DFT Guided Advanced E-Eye Sensing Technique for On-site Quantification of Fe, Cr, F, and As in the Environmental, Biological, and Food Samples
09:51

TD-DFT Guided Advanced E-Eye Sensing Technique for On-site Quantification of Fe, Cr, F, and As in the Environmental, Biological, and Food Samples

Published on: September 19, 2025

608

Area of Science:

  • Biochemistry
  • Pharmacology
  • Spectroscopy

Background:

  • Arsenic trioxide (ATO) is an effective anticancer drug for acute promyelocytic leukemia (APL).
  • Serum albumin, abundant in plasma, is a primary transporter for many drugs.
  • Understanding drug-protein interactions is crucial for effective drug delivery.

Purpose of the Study:

  • To investigate the binding interaction between arsenic trioxide and serum albumins (human and bovine).
  • To evaluate the potential of human serum albumin (HSA) and bovine serum albumin (BSA) as carriers for arsenic trioxide delivery.

Main Methods:

  • Fourier-transform infrared (FTIR) spectroscopy.
  • UV-Vis spectroscopy.
  • Analysis of binding modes, constants, and effects on protein structure and stability at physiological conditions.

Main Results:

  • Arsenic trioxide binding altered protein conformation, reducing alpha-helix content and increasing turn structure, indicating partial destabilization.
  • Binding constants for ATO-HSA and ATO-BSA were determined as 1.07×10(4) M⁻¹ and 1.27×10(4) M⁻¹, respectively.
  • Spectroscopic data confirmed the interaction and structural changes upon complexation.

Conclusions:

  • Serum albumins (HSA and BSA) demonstrate significant binding affinity for arsenic trioxide.
  • These findings suggest that serum albumins can serve as viable carriers for targeted arsenic trioxide delivery.